241 related articles for article (PubMed ID: 31324223)
1. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Hurkmans DP; Basak EA; van Dijk T; Mercieca D; Schreurs MWJ; Wijkhuijs AJM; Bins S; Hoop EO; Debets R; Joerger M; Odink A; van der Veldt AAM; van der Leest CH; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2019 Jul; 7(1):192. PubMed ID: 31324223
[TBL] [Abstract][Full Text] [Related]
2. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies.
Zhang J; Sanghavi K; Shen J; Zhao X; Feng Y; Statkevich P; Sheng J; Roy A; Zhu L
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):962-970. PubMed ID: 31710163
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
5. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
[TBL] [Abstract][Full Text] [Related]
6. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J; Cai J; Bello A; Roy A; Sheng J
J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer.
Tohi M; Irie K; Mizuno T; Okuyoshi H; Hirabatake M; Ikesue H; Muroi N; Eto M; Fukushima S; Tomii K; Hashida T
Ther Drug Monit; 2023 Feb; 45(1):110-116. PubMed ID: 35830878
[TBL] [Abstract][Full Text] [Related]
9. The impact of corticosteroid use during anti-PD1 treatment.
Pan EY; Merl MY; Lin K
J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR; Drake CG; Wollner I; Powderly JD; Picus J; Sharfman WH; Stankevich E; Pons A; Salay TM; McMiller TL; Gilson MM; Wang C; Selby M; Taube JM; Anders R; Chen L; Korman AJ; Pardoll DM; Lowy I; Topalian SL
J Clin Oncol; 2010 Jul; 28(19):3167-75. PubMed ID: 20516446
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
Sheng J; Zhang J; Baudelet C; Roy A
J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.
Hamuro L; Statkevich P; Bello A; Roy A; Bajaj G
Clin Pharmacol Ther; 2019 Nov; 106(5):1018-1027. PubMed ID: 31090921
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Goldschmidt JH; Chou LN; Chan PK; Chen L; Robert N; Kinsey J; Pitts K; Nestor M; Rock EP; Lazarus HM
Cancer Med; 2023 Nov; 12(22):20783-20797. PubMed ID: 37962239
[TBL] [Abstract][Full Text] [Related]
14. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
15. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
16. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
19. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
Sabatier R; Nicolas E; Paciencia M; Jonville-Béra AP; Madroszyk A; Cecile M; Braticevic C; Duran S; Tassy L; Rouby F; Micallef J; Rousseau F
J Geriatr Oncol; 2018 Sep; 9(5):494-500. PubMed ID: 29530494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
